Viking Therapeutics GLP-1/GIP drug trial success
VIKING THERAPEUTICSVIGVIGI
Statements (3)
- Neutral
Viking Therapeutics reported a successful weight-loss drug trial addressing GLP-1 therapy weakness.
- Bullish
Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data
- Bullish
Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly's Zepbound.